Response
In our recent article, 1 we concluded that "under physiological conditions, the intravenous GPIIb/IIIa antagonists currently in use, as well as the oral GPIIb/IIIa antagonist xemilofiban, do not have an intrinsic activating property that results in platelet aggregation or stable fibrinogen binding to GPIIb/IIIa." We do not question the ability of GPIIb/IIIa blockers to induce a fibrinogen-binding competent conformation of GPIIb/IIIa that can be preserved by (nonphysiological) chemical fixation, as first described in 1991 by Du et al, 2 and confirmed and extended in 1998 by Peter et al, 3 and more recently us 1 ( Figure 5 ). However, this conformational change is readily reversible in intact (nonfixed) platelets (see Discussion in Frelinger et al 1 ). Thus, as Peter et al point out in their letter, the important question to be addressed is whether, under physiological conditions, GPIIb/IIIa reverts to a resting state or binds fibrinogen and mediates platelet aggregation. We addressed this question by incubating intact platelets with a wide range of GPIIb/IIIa antagonist concentrations (without chemical fixation) under conditions in which the antagonists bind reversibly and found no evidence of platelet aggregation, increased fibrinogen binding, or P-selectin expression (Figures 1, 2 , and 3 open bars, and Figure 4 ). 1 The studies cited in Peter et al's letter 4 -6 also demonstrated no direct activating effect of GPIIb/IIIa antagonists: (1) exposure of platelets to abciximab or orbofiban did not increase binding of the activation-dependent antibody PAC1 to GPIIb/IIIa 4 ; (2) neither abciximab nor orbofiban by themselves induced thromboxane generation 5 ; (3) none of the GPIIb/IIIa antagonists tested, including tirofiban, increased intracellular Ca 2ϩ concentrations in nonactivated platelets. 6 We strongly disagree with Peter et al's interpretation of results shown in our Figure 3 . 1 The increased fibrinogen binding shown was blocked by addition of hirudin, indicating that thrombin, not abciximab, was responsible for platelet activation.
Neither our study, 1 nor that of Peter et al, 3 addressed the separate, but very important, question of whether the GPIIb/ IIIa antagonists enhance platelet activation stimulated by traditional platelet agonists. While results from various studies 4 -6 are consistent with this hypothesis, they may only apply to selected GPIIb/IIIa antagonists. For example, although orbofiban enhanced thromboxane production stimulated by CD41-induced clustering of GPIIb/IIIa receptors, abciximab did not. 6 Therefore, we agree with Peter et al that additional studies specifically addressing this potential effect are needed.
In summary, as we previously concluded, 1 based on our results 1 and those of others, 4 -6 the evidence is that, under physiological conditions, currently approved GPIIb/IIIa antagonists do not directly stimulate platelet aggregation or stable fibrinogen binding.
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